The company said that its 2019-nCoV (SARS-CoV-2) IgG/IgM kits can help labs and hospitals with early diagnosis and elimination of suspicious cases.
Public Health England will use the company's Victor EnLite instrument and EnLite Neonatal TREC kit at three of six sites to evaluate screening newborns for "Bubble Boy" disease.
The system, called Galen Prostate, uses a proprietary algorithm to help pathologists detect and grade prostate cancer in biopsies.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
The organization is looking to fund new tests for rapid detection, stratification, and monitoring of patients.
The firm said that its Affimer reagents may provide a better solution than antibodies in some applications for diagnostic test developers.
The company said the system combined with its Vitros XT 7600 Integrated System completes its suite of Vitros XT Solutions for laboratories.
In the quarter, the firm entered a partnership with Specific Diagnostics and also submitted an enhanced version of its blood culture ID panel for regulatory clearance.
Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.
The partners are validating three rapid diagnostic test prototypes prior to initiating a trial in the Democratic Republic of the Congo during March 2020.